WO2010057036A3 - Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof - Google Patents

Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof Download PDF

Info

Publication number
WO2010057036A3
WO2010057036A3 PCT/US2009/064455 US2009064455W WO2010057036A3 WO 2010057036 A3 WO2010057036 A3 WO 2010057036A3 US 2009064455 W US2009064455 W US 2009064455W WO 2010057036 A3 WO2010057036 A3 WO 2010057036A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid composition
methods
low
active agents
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/064455
Other languages
French (fr)
Other versions
WO2010057036A2 (en
Inventor
Chandir Ramani
Juan Wang
Anil Kane
Kwok Chow
Joe Lambing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Inc
Portola Pharmaceuticals LLC
Original Assignee
Patheon Inc
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010057036(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2743639A priority Critical patent/CA2743639A1/en
Priority to JP2011536535A priority patent/JP2012508773A/en
Priority to EP09759842A priority patent/EP2376065A2/en
Priority to CN2009801536827A priority patent/CN102271663A/en
Priority to MX2011005128A priority patent/MX2011005128A/en
Application filed by Patheon Inc, Portola Pharmaceuticals LLC filed Critical Patheon Inc
Priority to RU2011123377/15A priority patent/RU2011123377A/en
Priority to BRPI0921049A priority patent/BRPI0921049A2/en
Priority to AU2009313867A priority patent/AU2009313867A1/en
Publication of WO2010057036A2 publication Critical patent/WO2010057036A2/en
Anticipated expiration legal-status Critical
Publication of WO2010057036A3 publication Critical patent/WO2010057036A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37oC; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCELTM, POLYOXTM WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.
PCT/US2009/064455 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof Ceased WO2010057036A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2009313867A AU2009313867A1 (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
JP2011536535A JP2012508773A (en) 2008-11-14 2009-11-13 Solid composition for controlled release of poorly water soluble ionizable active agents at low pH and methods of use thereof
EP09759842A EP2376065A2 (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
CN2009801536827A CN102271663A (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
MX2011005128A MX2011005128A (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof.
CA2743639A CA2743639A1 (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
RU2011123377/15A RU2011123377A (en) 2008-11-14 2009-11-13 SOLID COMPOSITION FOR CONTROLLED RELEASE OF ACTIVE IONIZABLE AGENTS CHARACTERIZED BY LOW SOLUBILITY IN WATER AT LOW pH VALVES AND METHODS OF ITS APPLICATION
BRPI0921049A BRPI0921049A2 (en) 2008-11-14 2009-11-13 solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods for use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11500808P 2008-11-14 2008-11-14
US11494108P 2008-11-14 2008-11-14
US61/115,008 2008-11-14
US61/114,941 2008-11-14

Publications (2)

Publication Number Publication Date
WO2010057036A2 WO2010057036A2 (en) 2010-05-20
WO2010057036A3 true WO2010057036A3 (en) 2011-06-09

Family

ID=41466672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064455 Ceased WO2010057036A2 (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof

Country Status (13)

Country Link
US (2) US20100151019A1 (en)
EP (1) EP2376065A2 (en)
JP (1) JP2012508773A (en)
KR (1) KR20110097829A (en)
CN (1) CN102271663A (en)
AR (1) AR074347A1 (en)
AU (1) AU2009313867A1 (en)
BR (1) BRPI0921049A2 (en)
CA (1) CA2743639A1 (en)
CL (1) CL2009002073A1 (en)
RU (1) RU2011123377A (en)
TW (1) TW201022253A (en)
WO (1) WO2010057036A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
KR101738369B1 (en) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 Hot-melt extruded controlled release dosage form
CN102639118B (en) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 Oxidation-stabilized tamper resistant dosage form
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
DK3564357T3 (en) 2010-02-01 2022-06-20 Rebiotix Inc BACTERIA THERAPY AGAINST CLOSTRIDIUM DIFFICILE COLITIS
ES2606227T3 (en) 2010-02-03 2017-03-23 Grünenthal GmbH Preparation of a pharmaceutical powder composition by an extruder
TWI516286B (en) 2010-09-02 2016-01-11 歌林達股份有限公司 Tamper resistant dosage form comprising an anionic polymer
BR112013005194A2 (en) 2010-09-02 2016-05-03 Gruenenthal Gmbh tamper-resistant dosage form comprising inorganic salt
JP2013544271A (en) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド Pharmaceutical compositions, dosage forms, and novel forms of the compounds of formula (I) and methods of use thereof
EA201400172A1 (en) 2011-07-29 2014-06-30 Грюненталь Гмбх SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES
BR112014001091A2 (en) 2011-07-29 2017-02-14 Gruenenthal Gmbh tamper resistant tablet that provides immediate release of the drug
ES2655942T3 (en) * 2011-09-02 2018-02-22 Novartis Ag Choline salt of a substituted cyclobutanedione anti-inflammatory compound
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SI2846835T1 (en) 2012-05-11 2018-01-31 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2536836T3 (en) * 2012-10-12 2015-05-29 Omya International Ag Formulation of gastro-retentive medication and release systems and their method of preparation using calcium carbonate transformed into functional
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
KR102099503B1 (en) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 Microbiota restoration therapy (mrt) compositions
BR112016000194A8 (en) 2013-07-12 2019-12-31 Gruenenthal Gmbh tamper-resistant dosage form containing ethylene vinyl acetate polymer
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (en) 2014-05-26 2017-05-31 Грюненталь Гмбх DOSAGE FORM AS PARTICLE MULTIPLE, PROTECTED AGAINST CALLED DOSE RESET BY ETHANOL
MA40071A (en) * 2014-07-01 2016-01-07 Probi Usa Inc Bi-layer dual release probiotic tablets
US9962349B2 (en) * 2014-10-17 2018-05-08 Fidia Farmaceutici S.P.A. Dermal therapeutic system with high adhesivity
JP6532153B2 (en) * 2015-01-30 2019-06-19 ライオン株式会社 Internally pilled tablets
EP3253376A1 (en) 2015-02-03 2017-12-13 Grünenthal GmbH Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10828340B2 (en) * 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) * 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
CN110869007B (en) * 2017-06-23 2022-10-14 太阳医药高级研究有限公司 Abuse-resistant oral solid dosage form
JP7158189B2 (en) * 2018-07-11 2022-10-21 東洋電装株式会社 throttle grip device
GB2642921A (en) * 2023-03-06 2026-01-28 Welfare Concepts Ltd Sustained release solid oral bolus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228411A1 (en) * 2005-04-11 2006-10-12 Huailiang Wu Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US20070123547A1 (en) * 2005-11-03 2007-05-31 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US20080279845A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228411A1 (en) * 2005-04-11 2006-10-12 Huailiang Wu Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US20070123547A1 (en) * 2005-11-03 2007-05-31 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US20080279845A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEKA L. ET AL.: "Design and evaluation of polymeric coated minitablets as multiple unit gastroretentive floating drug delivery systems for furosemide.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 98, no. 6, 13 November 2008 (2008-11-13), pages 2122 - 2132, XP002629134, DOI: 10.1002/jps.21562 *
RIIS ET AL: "pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 65, no. 1, 1 December 2006 (2006-12-01), pages 78 - 84, XP005788727, ISSN: 0939-6411, DOI: DOI:10.1016/J.EJPB.2006.07.001 *

Also Published As

Publication number Publication date
TW201022253A (en) 2010-06-16
AU2009313867A1 (en) 2011-06-30
RU2011123377A (en) 2012-12-20
WO2010057036A2 (en) 2010-05-20
JP2012508773A (en) 2012-04-12
AR074347A1 (en) 2011-01-12
KR20110097829A (en) 2011-08-31
CA2743639A1 (en) 2010-05-20
CN102271663A (en) 2011-12-07
US20100151019A1 (en) 2010-06-17
CL2009002073A1 (en) 2010-12-24
BRPI0921049A2 (en) 2017-03-28
EP2376065A2 (en) 2011-10-19
US20130172374A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
WO2010057036A3 (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
WO2006122828A3 (en) Optimized injection formulation for rna
WO2008137758A3 (en) Amino acid lipids and uses thereof
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
MX2008016508A (en) Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders.
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
MX2009003030A (en) Galenic form for the trans-mucosal delivery of active ingredients.
MX2009004439A (en) Ibuprofen composition.
NZ585219A (en) Fast release solid formulation, preparation and use thereof
WO2008045806A3 (en) Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions
WO2009135178A3 (en) Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
WO2007037653A8 (en) Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
EP1905426A3 (en) Anti-acid pharmaceutical composition in powder form; pharmaceutical preparation containing it and process for making it
WO2008133157A1 (en) Body-temperature lowering depressant
AR060869A1 (en) SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA
MX2010003594A (en) Crystalline forms of dmxaa sodium salt.
WO2008055254A3 (en) Formulations and methods for oral delivery of proteins
AR067048A1 (en) ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.
WO2006121522A3 (en) Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells
EP1552838A4 (en) COMPOSITION CONTAINING RUBROBUSARIN GLYCOSIDE
ECSP099251A (en) PHARMACEUTICAL FORMULATIONS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980153682.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759842

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2743639

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005128

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011536535

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 4161/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009759842

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117013465

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011123377

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009313867

Country of ref document: AU

Date of ref document: 20091113

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0921049

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110513